Evaluation of the effects of Gabapentin vaginal gel on Dyspareunia

Phase 3

Recruiting

• Conditions: Dyspareunia.; Dyspareunia; N94.1

• Registration Number: IRCT20191106045356N13
• Lead Sponsor: Yazd University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

married
Suffering from Dyspareunia
Insensitivity to gabapentin and vaginal gel base ingredients
Not taking vaginal painkillers or systemic gabapentin one week before the start of the study
Consent to participate in the study and complete the informed consent form

Exclusion Criteria

History of psychiatric diseases
Acute and chronic vaginal infection
cancer of the female genital tract
Pregnancy and breastfeeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SR Pain Scale. Timepoint: Measurement of NRS scale at the beginning of the study and on days 7, 14, 21 and 28 days after the start of gabapentin gel consumption. Method of measurement: NRS Scale.